Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29228879 | 0.89 | PKM (0.53) | CYP2C9MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL29228903 | 0.85 | MEN1 (0.55) | MEN1KMT2AESR2AKR1C3AKR1C1 | |
| SCHEMBL30458179 | 0.84 | RAB9A (0.41) | CYP2C9MEN1KMT2AESR2ALDH1A1 | |
| SCHEMBL976255 | 0.83 | CYP2C9 (0.51) | CYP2C9KMT2AALDH1A1RAB9AKDM4E | |
| SCHEMBL12922702 | 0.78 | ALDH1A1 (0.43) | CYP2C9MEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL29228895 | 0.76 | CYP2C9 (0.46) | CYP2C9MEN1KMT2AALDH1A1CYP2C19 | |
| SCHEMBL29228917 | 0.76 | PKM (0.58) | ALDH1A1RAB9ACYP2C19AKR1C3GAA | |
| SCHEMBL30458160 | 0.76 | TMEM97 (0.54) | HRH3 | |
| SCHEMBL30458157 | 0.76 | TMEM97 (0.54) | HRH3 | |
| SCHEMBL11181755 | 0.75 | MAOA (0.50) | MEN1KMT2AALDH1A1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | CYP2C9 1966/4885MEN1 3634/4885KMT2A 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.